Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting
DIGESTIVE AND LIVER DISEASE(2018)
摘要
Background and aims: The 2017 EASL HBV CPG recommend switching TDF treated patients to TAF (NUC naïve or experienced) or ETV (only NUC naïve) if they have one of the following risk factors: (1) age >60 years, (2) bone disease [history of fragility fracture, osteoporosis, chronic use of steroids or medications that worsen BMD], and (3) renal alterations [eGFR <60 mL/min, albuminuria >30 mg/24 h or moderate dipstick proteinuria, low serum phosphate (<2.5 mg/dL), or hemodialysis]. We want to estimate the number of patients who could benefit from this switch in a cohort of TDF-treated patients.
更多查看译文
关键词
tenofovir alafenamide,tenofovir difumarate,entecavir,long-term,real-life
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要